The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. [electronic resource]
Producer: 20191113Description: 2240-2246 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab -- therapeutic use
- Capecitabine -- therapeutic use
- Colorectal Neoplasms -- drug therapy
- Female
- Gene Expression Profiling
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Mitomycin -- therapeutic use
- Prognosis
- Progression-Free Survival
- Transcriptome -- genetics
No physical items for this record
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.